Skip to main
TVGN

TVGN Stock Forecast & Price Target

TVGN Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tevogen Bio Holdings is positioned for success with its ExacTcell platform targeting a wide range of diseases and driving innovation with Tevogen.AI. Their strategy to expand into potential initiatives in generics, biosimilars, devices, and insurance-linked healthcare solutions shows their ambition to grow as an integrated and scalable healthcare enterprise, although there are inherent risks involved in these ventures.

Bears say

Tevogen Bio Holdings is in its early stages of development and has a diversified pipeline addressing various medical indications, but its lack of current revenue and negative earnings outlook warrants caution for investors. The recent share price decline may also impact the company's capital formation and balance sheet flexibility, and a potential acquisition of a contract research organization may not be enough to offset these concerns in the short term. Additionally, the company's plan to evaluate additional life sciences-related transactions signals a broad ambition to build an integrated healthcare enterprise, which could create added complexity and financial strain for the company.

TVGN has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Semper Paratus Acquisition Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Semper Paratus Acquisition Corp (TVGN) Forecast

Analysts have given TVGN a Strong Buy based on their latest research and market trends.

According to 1 analysts, TVGN has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Semper Paratus Acquisition Corp (TVGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.